HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
Open Access
- 22 January 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Public Health
- Vol. 9 (1), 34
- https://doi.org/10.1186/1471-2458-9-34
Abstract
Background Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed. Methods Literature and international health databases were systematically searched for HCV-specific burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and liver transplantation. Data were collected for the WHO European region with emphasis on 22 countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions. Results HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national surveillance are not fully comparable and need to be standardised. HCV prevalence data are often inconclusive. According to available data, an estimated 7.3–8.8 million people (1.1–1.3%) are infected in our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable. Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2 million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by patients in preventable disease stages. About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV. Conclusion Our results indicate that hepatitis C is a major health problem and highlight the importance of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce, outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries. What is needed are public awareness, co-ordinated action plans, and better data. European physicians should be aware that many infections are still undetected, provide timely testing and antiviral treatment, and avoid iatrogenic transmission.Keywords
This publication has 60 references indexed in Scilit:
- Impaired health‐related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levelsJournal of Viral Hepatitis, 2006
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Symptom Prevalence and Clustering of Symptoms in People Living with Chronic Hepatitis C InfectionJournal of Pain and Symptom Management, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- Hepatitis CPharmacoEconomics, 2006
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis CJournal of Hepatology, 2005
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002Hepatology, 2002
- Emerging Infectious Diseases in Russia, 1990-1999Emerging Infectious Diseases, 2001
- Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology, 1998